

Ocrevus™ (ocrelizumab)



When requesting Ocrevus™ (ocrelizumab), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication(s)

Ocrevus is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.

Coverage Guidelines

The individual meets **all** of the following criteria for approval:

- 1) Has either relapsing form of multiple sclerosis (MS) or primary progressive MS; AND
- 2) Is 18 years of age or older; AND
- 3) Not used in combination with other disease modifying MS agent(s); AND
- 4) Prescribed by or in consultation with a physician who specializes in the treatment of multiple sclerosis (MS) and/or a neurologist

Approval duration (initial and renewal): 12 months

Recommended Dosing

The initial dose is 300mg IV, followed 2 weeks later by a second 300mg IV infusion; OR Maintenance doses are 600mg by IV infusion once every 6 months.

References

1. Ocrevus™ injection for intravenous infusion [prescribing information]. San Francisco, CA: Genentech, Inc (a Member of the Roche Group); March 2017.
2. Hauser SL, Bar-Or A, Comig G, et al, for the OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med*. 2017;376(3):221-234.
3. Montalban X, Hauser SL, Kappos L, et al, for the ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med*. 2017;376(3):209-220.
4. Clinical bulletin. Information for health professionals. Overview of multiple sclerosis. Rosalind Kalb and Nancy Reitman. ©2012 National Multiple Sclerosis Society. Available at: http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Clinical_Bulletin_Overview-of-Multiple-Sclerosis.pdf. Accessed on March 16, 2018.
5. Consensus Paper by the Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. Updated March 2017. Available at: http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf. Accessed on March 16, 2018.
6. Gajofatto A, Turatti M, Benedetti MD. Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. *Expert Rev Neurother*. 2017;17(4):393-406.